VIENNA--(BUSINESS WIRE)-- Data from LUX-Lung 3, the largest and most robust registration trial to datea in patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC) shows that the novel compound afatinib*, an irreversible ErbB Family Blocker, leads to better and longer control and improvement of the most common lung cancer-related symptoms and better quality of life (QoL) compared to chemotherapy (pemetrexed and cisplatin), considered best-in-class for non-squamous NSCLC.1,2 These findings further reinforce the outstanding first-line efficacy of afatinib* in patients with EGFR mutation positive NSCLC.
